key: cord-0277256-8ok0yy87
authors: Honda-Okubo, Yoshikazu; Li, Lei; Baldwin, Jeremy; Petrovsky, Nikolai
title: Accelerated vaccine induction of IgM neutralising antibody enables vaccine protection against same day lethal influenza virus challenge
date: 2021-02-18
journal: bioRxiv
DOI: 10.1101/2021.02.17.431751
sha: 52fead2786dcaf16ef37d73b9acaa2d68283f179
doc_id: 277256
cord_uid: 8ok0yy87

Novel influenza strains to which humans have no pre-existing immunity can trigger global pandemics without warning. Current pandemic vaccines typically require two doses and up to 6 weeks to induce protective immunity. In addition, to their role in increasing vaccine-induced immune response, adjuvants may also play a part in reducing the time between immunization and vaccine protection, although this role has seldom been previously explored in literature. This study assessed the speed of protection achievable with a standard inactivated influenza vaccine when formulated with or without a novel delta-inulin adjuvant (Advax). When formulated with Advax adjuvant mice were protected even when the vaccine was administered intramuscularly contemporaneously with a lethal intranasal virus challenge. The protection was found to be B-cell dependent and transfer of day 6 immune serum from mice immunised with Advax-adjuvanted influenza vaccine conferred protection to naïve animals. This protection was shown to be mediated by vaccine induced IgM rather than IgG neutralising antibodies. The results show that influenza vaccine can be formulated to provide immediate protection following immunization with this novel concept warranting testing in human trials. IMPORTANCE In the past 100 years there have been several major influenza pandemics that resulted in significant loss of life. The time taken for individuals to develop vaccine protection is an important factor in curbing the spread of infection and reducing pandemic mortality rates. Current influenza vaccines can take up to 5-6 weeks to generate full protection leaving front-line heath care workers and others, at risk for an extended period of time. Our novel accelerated vaccine protection approach provides effectively immediate vaccine protection against lethal virus challenge. This would assist front-line workers to continue to provide essential services and maintain critical infrastructure during pandemic. The study also highlights the often-overlooked role that antigen-specific IgM plays in virus protection and provides a novel adjuvanted strategy for enlisting IgM to provide accelerated vaccine protection.

Influenza remains a serious public health threat and kills up to 650,000 people worldwide 60 annually according to the World Health Organisation (1) . In addition to seasonal epidemic 61 influenza, pandemics caused by novel influenza strains have occurred 5 times in the last 62 hundred years, resulting in a significant loss of life and impacting the global economy (2). 63

The most recent pandemic, A(H1N1)pdm09, in 2009 rapidly spread to over 74 countries 64 within 2 months after its initial appearance in North America (3). Due to the ability of 65 influenza to rapidly develop resistance to antiviral drugs and antibodies (4), vaccination is 66 the single most effective strategy against influenza. However, unlike drug treatment in 67 which the mode of action is immediate, vaccines can take several doses over many weeks to 68 achieve protection. In a pandemic time is a critical factor, highlighting the need to develop 69 vaccine formulations that can reduce the lag time between initial vaccination and immune with an imiquimod adjuvant showed no protection immediately after vaccination and only 78 35% protection if challenged 1 day after vaccination (5). An inactivated H1N1 vaccine 79 similarly provided only modest protection mediated by innate immunity to a sublethal 80 challenge (6). Hence the literature to date has suggested that it is not possible to sufficiently 81 accelerate adaptive immunity in order to provide vaccine protection against an immediate 82 virus challenge, with only innate immunity being invoked as a source of relatively weak early 83 protection. 84 85 Advax is a novel polysaccharide adjuvant based on semi-crystalline microparticles of delta 86 inulin that has a proven track record of boosting vaccine responses and enhancing 87 protection across a wide range of infectious diseases including Influenza (7) (8) (9), Japanese 88 Encephalitis (10), West Nile virus (11), Ebola (12), SARS CoV (13), MERS CoV (14), 89 7 lungs at 5-7dpc showed a progressive decrease in lung virus load in both vaccine groups, 141 with a trend to a lower virus load in the Advax-adjuvanted group, although this difference 142 did not reach statistical significance. 143 144 Accelerated Protection with Advax-adjuvanted vaccine is B-cell and antibody dependent. 145

To define the mechanism responsible for the accelerated protection, B-cell deficient mice 146 (µMT strain) and mice depleted of CD4+ and/or CD8+ T-cells using monoclonal antibodies 147

were challenged with a lethal dose of PR8 virus immediately after immunization. The 148 accelerated protection induced by Advax-adjuvanted iPR8 was completely abrogated in the 149 µMT but not the T cell depleted mice, indicating the accelerated protection was B-cell and 150

not T-cell dependent. Furthermore, passive transfer into naïve mice of sera collected 6dpc 151 from immunised/challenged mice, also conferred protection ( Figure 5 ). These results 152

indicate that the accelerated protection in Advax-adjuvanted iPR8 immunised mice is 153 mediated by antigen-specific antibodies. 154 155

Analysis of sera at 6dpc showed that influenza-specific IgM levels were significantly 157 increased in the Advax-adjuvanted vaccine group compared to vaccine alone, while IgG 158 levels were low with no major differences between groups. To confirm the specific isotypes 159 involved in accelerated protection, size-exclusion chromatography was used to separate and 160 pool the two main types of antibodies, IgG and IgM, from the 6dpc immunoglobulin 161 fractions of mice simultaneously immunized and challenged ( Figure 6B -C). An HAI assay 162 confirmed that 6dpc IgM was far more potent at neutralising influenza virus (1:640) when 163 compared to 6dpc IgG (1:10) ( Figure 6D) . Finally, to confirm the immune IgM was 164 responsible for accelerated protection in the Advax-adjuvanted iPR8 immunised mice, the 165 purified 6dpc IgM was mixed with a lethal dose of PR8 virus used to challenge naïve mice. This study showed the ability using an appropriate vaccine strategy to accelerate the 184 development of protective adaptive immunity against an otherwise lethal influenza 185 infection. Notably, this protection was not mediated through innate immunity which is 186 typically thought to be the only arm of the immune system able to respond this rapidly, as 187 highlighted by the fact that the vaccine or Advax adjuvant on their own had no protective 188 effect. In particular, it was the ability of the Advax adjuvant to induce rapid production of 189 influenza-specific IgM with influenza neutralisation capacity that explained how the vaccine 190 was able to outrace the virus and protect against an otherwise highly lethal infection. Lung Reaction was stopped by adding 100µl of 1M Phosphoric Acid. The optical density was 319 measured at 450nm (OD 450nm ) using an automated spectrophotometer plate reader 320 (VersaMax, Molecular Devices, CA, U.S.A.) and analyzed using SoftMax Pro Software. 321

Hemagglutination inhibition (HI) assay was performed as described previously using 1% 322 guinea pig red blood cells as described (7). 

Influenza (Seasonal)

A history of influenza

Initial human transmission dynamics of the pandemic 460 (H1N1) 2009 virus in North America

Emerging influenza antiviral resistance threats

Immediate and broad-464 spectrum protection against heterologous and heterotypic lethal challenge in mice by live 465 influenza vaccine

Inactivated influenza vaccine that provides rapid

innate-immune-system-mediated protection and subsequent long-term adaptive immunity

Advax™, a polysaccharide adjuvant 471 derived from delta inulin, provides improved influenza vaccine protection through broad-472 based enhancement of adaptive immune responses

A single immunization with 474 inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) 475 overcomes pregnancy-associated immune suppression and enhances passive neonatal 476 protection

Delta inulin polysaccharide adjuvant enhances the ability of split-479

virion H5N1 vaccine to protect against lethal challenge in ferrets

JE-ADVAX vaccine 481 protection against Japanese encephalitis virus mediated by memory B cells in the absence of 482

CD8+ T cells and pre-exposure neutralizing antibody

An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax

a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous 486 and heterologous flaviviruses

Adjuvant selection impacts the correlates of vaccine protection against Ebola 489 infection

Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta 492 inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic 493 immunopathology

Efficacy of an adjuvanted Middle East respiratory 496 syndrome coronavirus spike protein vaccine in dromedary camels and alpacas

Delta 499 inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and 500 protection against Mycobacterium tuberculosis infection

An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with 503 great breadth and potency

Petrovsky 505 NJV

pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with 510

Advax™ delta inulin adjuvant

Delta inulin adjuvant 512 enhances plasmablast generation, expression of activation-induced cytidine deaminase and 513

B-cell affinity maturation in human subjects receiving seasonal influenza vaccine

Heterosubtypic immunity to influenza A virus infection requires a 517 properly diversified antibody repertoire

Influenza: the once and future pandemic

Are we ready for pandemic influenza?

Adjuvanted influenza vaccines

Role of natural and immune IgM antibodies in immune responses

IgM in microbial infections: taken for granted?

Ehrenstein MR, Notley CA. 2010. The importance of natural IgM: scavenger, 531 protector and regulator

Functional roles of the igm fc receptor in the immune system

B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the 537 protective response to influenza virus infection

Of mice and not men: differences between mouse and 540 human immunology

Animal models for influenza virus pathogenesis and 542 transmission

Viral loads in the lung were determined in 20% homogenates by plaque assay (B). Each bar 393represents the mean ± SD (5 mice lungs per time point group). Statistical analysis: Mann-394 Whitney test. *; p < 0.05, ns; no significance. 395